Last deal

Amount

Series B

Stage

09.11.2023

Date

2

all rounds

$15.68M

Total amount

date founded

Financing round

General

About Company
Rijing Biosciences develops molecular diagnostic technology for thyroid cancer detection.

Industry

Sector :

Subsector :

Also Known As

RigenBio, Ruijing Bio, Rui Jing Bio, Ruijing Biology

founded date

01.01.2017

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The Shanghai-based company, founded in 2017, offers a range of products and services for the entire thyroid cancer diagnosis and treatment cycle. This includes thyroid biopsy needles, multi-gene qPCR detection, NGS detection, Thyroscan® thyroid nodule classifier, and targeted surgery. Their molecular diagnostic reagents enable medical professionals to deliver accurate and early diagnoses, improving patient outcomes. Rijing Biosciences is dedicated to the development, production, sales, and testing services of individual molecular diagnostic reagents.
Contacts
Similar Companies
1000
Biocartis

Biocartis

Biocartis is a molecular diagnostics company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Lausanne, Switzerland

total rounds

9

total raised

$418.09M

count Of Investments

2
Epigenomics

Epigenomics

Epigenomics is a molecular diagnostics company that develops and commercializes in vitro diagnostic tests for cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

Berlin, Germany

total rounds

7

total raised

$105.84M
Exosome Diagnostics

Exosome Diagnostics

Exosome Diagnostics develops biofluid-based molecular diagnostic tests for personalized medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

New York, NY, USA

total rounds

5

total raised

$138.48M
Nova Satra Dx

Nova Satra Dx

Nova Satra Dx is a molecular diagnostics company that develops innovative blood-based tests for cancer detection.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Diagnostics, Health Care

Location

Singapore

total rounds

2

total raised

$2.5M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$15.68M

Money Raised

Their latest funding was raised on 09.11.2023. Their latest investor Boyuan Capital. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
14.04.2022
3
$15.68M
Local Amount - CNY 100M

Jinsheng Group

Jinsheng Group is an investment company.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance

count Of Investments

2
BioTrack Capital

BioTrack Capital

BioTrack Capital is a China-based investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Shanghai, China

count Of Investments

55
Co-Investors
Investors
5
2

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series B
Yes
Series B
No
Venture - Series Unknown
Boyuan Capital

Boyuan Capital

Boyuan Capital is an investment platform established by Bosch group, focused on China's deep science and technology sector.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Artificial Intelligence

Location

Shanghai, China

count Of Investments

25

Jinsheng Group

Jinsheng Group is an investment company.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance

count Of Investments

2

Yinshengtai Capital

Yinshengtai Capital is a venture capital firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

count Of Investments

4

Activity

Recent News
0